Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
1281-1300 of 1,782 trials

Ewing Sarcoma: Dinutuximab Beta with Chemotherapy

We are studying a new treatment combining dinutuximab beta with standard chemotherapy for patients with GD2-positive Ewing sarcoma. The goal is to find the best dose and assess how well it works in improving patient outcomes.

Ewing Sarcoma>2 yearsSafety phase (I)No PlaceboStandard MedicinesOncologyPediatrics

New Method for Umbilical Vein Catheterization in Newborns

We are studying a new technique for umbilical vein catheterization to see if it helps newborns in circulatory arrest receive faster and more effective resuscitation. This trial compares the new method with standard practices in the delivery room.

Cardiorespiratory Arrest at Birth in Full-Term Newborns≤3 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesInternal MedicinePediatrics

Fecal Incontinence: Botulinum Toxin Injections

We are studying how botulinum toxin injections may improve rectal movement in patients with fecal incontinence. The trial will also look at the treatment's effectiveness, quality of life, and tolerance after one month.

Fecal Incontinence>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Melanoma, Breast Cancer, and Head & Neck Cancer: Contrast-Enhanced Ultrasound Study

We are exploring whether contrast-enhanced ultrasound can better locate sentinel nodes during surgery compared to the current standard method. This study aims to improve detection and potentially predict if the nodes are cancerous.

Breast CancerMelanomaHead and Neck Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOncologyOtolaryngology

Acute Myeloid Leukemia: Venetoclax and Azacitidine Study

We are comparing a new treatment combination with standard chemotherapy for patients with newly diagnosed acute myeloid leukemia and NPM1 mutations. The goal is to see if this new approach is more effective and easier to tolerate.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Tranexamic Acid for Reducing Blood Loss in Cesarean Deliveries with Placenta Previa

We are studying whether a low dose of tranexamic acid can help women with placenta previa experience less blood loss during cesarean delivery. This trial aims to improve safety and outcomes for mothers and their babies.

Placenta PreviaPostpartum Hemorrhage≤3 monthsConfirmation phase (III)Standard MedicinesGynecology and ObstetricsHematology

Congenital Hyperinsulinism: HM15136 Treatment Study

We are evaluating a new treatment for children with congenital hyperinsulinism to see if it is safe and helps reduce low blood sugar events. This study includes children aged 2 years and older.

Congenital Hyperinsulinism≤3 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementEndocrinologyPediatrics

Ovarian Cancer: Pembrolizumab with Chemotherapy

We are studying a new treatment combining pembrolizumab with chemotherapy for patients with small cell ovarian carcinoma. The goal is to see how well this combination works and to evaluate its safety.

Ovarian Small Cell Carcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

S-ketamine for Severe Acute Brain Injury

We are studying whether S-ketamine can help patients with severe acute brain injuries who have ongoing brain activity issues. The trial also looks at the safety of this treatment and its effects on recovery over six months.

Brain Hemorrhage and Injury>2 yearsMonitoring phase (IV)Standard MedicinesNeurologyOtolaryngology

Multiple Myeloma and Knee Surgery: Apixaban Study

We are comparing how the blood thinner Apixaban works in patients with newly diagnosed multiple myeloma and those undergoing knee replacement surgery. This study aims to understand its effects on blood clotting and how it behaves in the body.

Thromboembolism Prophylaxis>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyHematologyOncology

Schizophrenia: Biomarkers for Clozapine Response

We are investigating whether specific biomarkers can help predict how well individuals with schizophrenia respond to clozapine. This research may lead to more tailored treatments for those who need them.

Schizophrenia≤3 monthsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesNeurologyPsychiatry

Pancreatic Cancer: GEMBRAX and FOLFIRINOX Treatment Study

We are exploring a new treatment sequence for patients with locally advanced pancreatic cancer to see if it improves outcomes and tolerability. This study will help us understand its effects on survival and quality of life.

Non-resectable Pancreatic Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

Hypertrophic Cardiomyopathy: Bisoprolol vs. Verapamil

We are studying the effects of Bisoprolol and Verapamil on symptoms and heart function in patients with non-obstructive hypertrophic cardiomyopathy. Our goal is to see if these treatments can improve exercise capacity and reduce heart rhythm issues.

Non-obstructive Hypertrophic Cardiomyopathy3-6 monthsMonitoring phase (IV)Standard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Steroid Treatment for Wheezing in Children

We are studying whether a new steroid treatment can help prevent asthma in children who wheezed for the first time after a rhinovirus infection. The trial will also look at the frequency and severity of wheezing episodes over time.

Acute Wheezing/Bronchiolitis1-2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemotePediatricsPulmonology

Lower Risk MDS: Luspatercept and EPO Combination Study

We are studying a new treatment combining luspatercept with EPO for patients with lower risk MDS who haven't responded to previous therapies. The goal is to see if this combination helps improve blood counts and reduces the need for blood transfusions.

Myelodysplastic Syndromes>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Inflammatory Bowel Disease: Risankizumab-800CW Imaging Study

We are investigating the safety and effectiveness of a new imaging agent for patients with Inflammatory Bowel Disease. This study aims to improve how we visualize drug targeting and inflammation in the intestines.

Inflammatory Bowel Disease (IBD)1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyInfectious Diseases

Heart Procedure: Single vs. Dual Antiplatelet Therapy

We are comparing a single medication to a combination of two medications for patients after a heart procedure. The goal is to see if the single medication is just as safe and effective while reducing bleeding risks.

Atrial Fibrillation>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Pneumococcal Vaccine Response in Patients Without a Spleen

We are studying how the timing of pneumococcal vaccination affects immune response in patients who have had their spleen removed. This research may help improve vaccination strategies for asplenic individuals.

Asplenia>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementAllergologyHematologyInfectious Diseases

DENOCHARCOT Trial: DENOsumab for Charcot Foot in Diabetes

We are studying whether DENOsumab can effectively treat acute Charcot foot in people with diabetes. This trial compares the medication to a placebo to assess its impact on health outcomes.

Diabetic Charcot Foot1-2 yearsMonitoring phase (IV)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

Almagate for Heartburn in Pregnant Women

We are studying the safety of almagate for treating heartburn and reflux in pregnant women. The trial also examines how this treatment affects the health of the fetus and newborn.

Heartburn and Reflux>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyGynecology and Obstetrics